Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.89 CAD
Change Today +0.03 / 3.49%
Volume 151.2K
IMV On Other Exchanges
Symbol
Exchange
Toronto
OTC US
Frankfurt
As of 3:53 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

immunovaccine inc (IMV) Snapshot

Open
C$0.88
Previous Close
C$0.86
Day High
C$0.89
Day Low
C$0.88
52 Week High
08/25/14 - C$1.40
52 Week Low
06/17/14 - C$0.55
Market Cap
81.7M
Average Volume 10 Days
136.5K
EPS TTM
C$-0.08
Shares Outstanding
91.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOVACCINE INC (IMV)

Related News

No related news articles were found.

immunovaccine inc (IMV) Related Businessweek News

No Related Businessweek News Found

immunovaccine inc (IMV) Details

Immunovaccine Inc., a clinical-stage biopharmaceutical company, discovers and develops activators of the immune system to treat cancer and prevent infectious diseases. The company develops its products based on DepoVax vaccine-adjuvanting platform, a vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Its product candidates include DPX-Survivac, a therapeutic cancer vaccine, which has completed Phase I clinical trials for the treatment of ovarian and brain cancer; and DPX-0907, a therapeutic cancer vaccine that has completed Phase I clinical trials for the treatment of breast, ovarian, and prostate cancer. The company also develops pre-clinical stage vaccine product candidates for infectious diseases, including respiratory syncytial virus and anthrax. In addition, its product pipeline consists of DepoVax-validating partnered programs for addiction medicine and animal health. Immunovaccine Inc. was founded in 2000 and is headquartered in Halifax, Canada.

23 Employees
Last Reported Date: 03/20/15
Founded in 2000

immunovaccine inc (IMV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: C$200.0K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$128.8K
Compensation as of Fiscal Year 2013.

immunovaccine inc (IMV) Key Developments

Fred Ors Joins Immunovaccine Inc. as Chief Business Officer

Frederic Ors joined Immunovaccine Inc.'s senior management team in the newly created position of Chief Business Officer. Mr. Ors spent 13 years at Medicago Inc. in Quebec, most recently as Vice President of Business Development and Strategic Planning.

Immunovaccine Inc. Initiates Phase 2 Clinical Trial of DPX-Survivac Immunotherapy in Recurrent Lymphoma

Immunovaccine Inc. announced that it has treated the first patient with diffuse large B cell lymphoma (DLBCL) in a Phase 2 clinical study of its lead cancer immunotherapy DPX-Survivac. The company-sponsored trial is evaluating DPX-Survivac in combination with oral cyclophosphamide, an immune modulating agent, in patients with recurrent DLBCL. DPX-Survivac is designed to activate killer T cells of the immune system against the survivin antigen found in a wide variety of solid tumors and blood cancers. The open label Phase 2 study designed to evaluate the efficacy of DPX-Survivac will enroll up to 24 patients with recurrent survivin-expressing DLBCL. Investigators for the multi-site study will determine the percentage of patients with measurable disease who respond clinically to the DPX-Survivac therapy. Immune responses and changes in tumor biopsies from these patients will also be monitored. Positive results could provide rationale for the initiation of a pivotal trial of DPX-Survivac in recurrent DLBCL, which is considered an orphan drug indication. The trial is being conducted at the Ottawa Hospital Research Institute and the Odette-Sunnybrook Cancer Centre, with additional sites planned as the trial progresses. Lymphoma is the most common form of hematologic cancer in the developed world. According to the Leukemia and Lymphoma Society, there were more than 700,000 people in 2013 living with lymphoma or in remission from the disease. About 90% of cases are non-Hodgkin lymphoma (NHL) and about 40% of NHL cases are diagnosed as DLBCL. Initial treatment of DLBCL often involves various chemotherapeutic agents, with or without radiation therapy and supplemental drug therapy. In cases of relapse, the preferred treatment for many patients with DLBCL is an autologous stem cell transplant (ASCT). The DPX-Survivac therapy will be applied to patients who are not transplant candidates or who experience recurrence following a stem cell transplant and lack additional treatment options. In previous DPX-Survivac studies conducted in ovarian cancer patients, robust and durable CD8 T cell responses were observed in almost all patients receiving a specified regimen of the vaccine. Patients with a robust immune response to DPX-Survivac showed a trend of delayed disease progression which may potentially be attributed to the therapy. The vast majority of ovarian cancer patients enrolled in these studies were in remission with no evidence of disease. However one patient with measurable and stable disease achieved a 43% reduction in tumor size, demonstrating a durable clinical benefit associated with the DPX-Survivac therapy.

Immunovaccine Inc. Announces Audited Earnings Results for the Year Ended December 31, 2014; Adopts Advance Notice By-Law

Immunovaccine Inc. announced audited earnings results for the year ended December 31, 2014. For the year, the company’s net loss and comprehensive loss was CAD 6,568,000 for the year ended December 31, 2014 was CAD 1,887,000 higher than the net loss and comprehensive loss during the year ended December 31, 2013. This relates mainly to the CAD 1,002,000 increase in research and development (R&D) costs, a CAD 575,000 increase in accreted interest, a decrease in income tax recovery of CAD 232,000, and an increase of CAD 104,000 in business development expenses, offset by a decrease of CAD 27,000 in general and administration (G&A) expenses. On March 20, 2015, the board of directors of the company adopted an advance notice by-law. The purpose of the advance notice by-law is to establish the conditions and framework under which the shareholders may exercise their right to submit director nominations by fixing a deadline by which such nominations must be submitted by a shareholder to the company prior to any annual or special meeting of shareholders, and sets forth the information that a shareholder must include in the notice to the company for the notice to be in proper written form. The advance notice by-law is effective immediately and will be submitted to the shareholders for ratification at the next annual and special meeting of shareholders of the Corporation scheduled to be held on April 16, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMV:CN C$0.89 CAD +0.03

IMV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMV.
View Industry Companies
 

Industry Analysis

IMV

Industry Average

Valuation IMV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 10.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOVACCINE INC, please visit www.imvaccine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.